Coxsackievirus B serotype 1 antigens (CVB1 antigens)

Coxsackievirus B serotype 1 (CVB1) antigens are the protein components of the CVB1 virus, a member of the Enterovirus genus within the Picornaviridae family. These antigens include structural capsid proteins (VP1, VP2, VP3, and VP4) and non-structural proteins involved in viral replication and polyprotein processing. The capsid proteins, particularly VP1, are the primary targets for the host's immune response and are critical for viral attachment to host receptors such as the Coxsackievirus and Adenovirus Receptor (CAR) and Decay-Accelerating Factor (DAF) (Source: creative-diagnostics.com, mdpi.com). CVB1 is a significant human pathogen associated with acute illnesses like aseptic meningitis and myocarditis, and it is strongly linked to the initiation of pancreatic islet autoimmunity leading to Type 1 Diabetes (T1D) (Source: nih.gov, binasss.sa.cr). Therapeutic interventions targeting these antigens include the development of inactivated vaccines, such as the multivalent PRV-101, which aim to elicit neutralizing antibodies to prevent infection and its long-term autoimmune complications (Source: nih.gov, sanofi.us). Additionally, small molecule antivirals like pleconaril have been studied for their ability to bind the VP1 protein and inhibit viral uncoating (Source: nih.gov, medscape.com).

Other names

CVB1Coxsackievirus B1Coxsackie B1Enterovirus B serotype 1CVB1 structural proteinsCVB1 capsid proteins

Vaccines and immunoglobulins provide neutralizing antibodies that bind to viral capsid antigens (VP1-VP4), blocking attachment to host receptors (CAR/DAF) and preventing entry. Small molecule inhibitors like pleconaril and disoxaril bind to the hydrophobic pocket of the VP1 protein, preventing viral uncoating. Other agents like enviroxime target the 3A non-structural protein to inhibit viral RNA replication.